Incorporation of TIP (paclitaxel, ifosfamide, cisplatin) into first-line therapy for intermediate to poor risk testicular germ cell tumors with unfavorable marker decline after initial two cycles chemotherapy: A report of three cases

International Journal of Urology

Volumn 14, Issue 5, 2007, Pages 455-457

  Ishioka, Jun Ichiro ^a   Kageyama, Yukio ^a   Ichiyanagi, Nobutaka ^a   Fukuda, Hiroshi ^a   Higashi, Yotsuo ^a  

^a NONE   (Japan)

Author keywords

Cisplatin; Combined anti neoplastic agents; First line therapy; Germ cell neoplasm; Ifosfamide; Paclitaxel

Indexed keywords

BLEOMYCIN; CIMETIDINE; CISPLATIN; DEXAMETHASONE; DIPHENHYDRAMINE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; MESNA; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINBLASTINE;

ADULT; ALLERGIC REACTION; ARTICLE; CANCER CHEMOTHERAPY; CASE REPORT; CONTINUOUS INFUSION; DOSE RESPONSE; DRUG WITHDRAWAL; GERM CELL TUMOR; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; OBSERVATIONAL METHOD; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REMISSION; STANDARD; TREATMENT PLANNING; TREATMENT RESPONSE;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; HUMANS; IFOSFAMIDE; MALE; MIDDLE AGED; NEOPLASMS, GERM CELL AND EMBRYONAL; PACLITAXEL; RISK FACTORS; TESTICULAR NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 34248681858     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2007.01755.x     Document Type: Article

References (11)

1. Bosl GJ, Motzer RJ. Testicular germ-cell cancer. N. Engl. J. Med. 1997 337 : 242 53.
2. Motzer RJ, Mazumdar M, Sheinfeld J et al. Sequential dose-intensive Paclitaxel, Ifosfamide, Carboplatin, and etoposide salvage therapy for germ cell tumor patients. J. Clin. Oncol. 2000 18 : 1173 80.
3. Houck W, Abonour R, Vance G, Einhorn LH. Secondary leukemias in refractory germ cell tumor patients undergoing autologous stem-cell transplantation using High-Dose Etoposide. J. Clin. Oncol. 2004 22 : 2155 8.
4. Kondagunta GV, Bacik J, Donadio A et al. Combination of Paclitaxel, Ifosfamide, and Cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. J. Clin. Oncol. 2005 23 : 6549 55.
5. Motzer RJ, Sheinfeld J, Mazumdar M et al. Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer. J. Clin. Oncol. 2000 18 : 2413 18.
6. Mazumudar M, Bajorin DF, Bacik G, Higgins RJ, Motzer RJ, Bosl GJ. Predicting outcome to chemotherapy in patients with germ cell tumors: the value of the rate of decline of human chorionic gonadotrophin and alpha-fetoprotein during therapy. J. Clin. Oncol. 2001 19 : 2534 41.
7. Motzer RJ, Gulati SC, Crown JP et al. High-dose chemotherapy and autologous bone marrow rescue for patients with refractory germ cell tumors. Early intervention is better tolerated. Cancer 1992 69 : 550 6.
8. Nichols CR, Williams SD, Loehrer PJ et al. Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: a Southeastern Cancer Study Group and Southwest Oncology Group protocol. J. Clin. Oncol. 1991 9 : 1163 72.
9. Broun ER, Nichols CR, Turns M et al. Early salvage therapy for germ cell cancer using high dose chemotherapy with autologous bone marrow support. Cancer 1994 73 : 1716 20.
10. Lotz JP, Andre T, Donsimoni R et al. High dose chemotherapy with ifosfamide, carboplatin, and etoposide combined with autologous bone marrow transplantation for the treatment of poor-prognosis germ cell tumors and metastatic trophoblastic disease in adults. Cancer 1995 76 : 154 5.
11. Rosti G, De Giorgi U, Salvioni R. Salvage high-dose chemotherapy in patients with germ cell tumors: an Italian experience with 84 patients. Cancer 2002 95 : 309 15.